Phillip Capital
Revenue was below our/consensus estimates due to flattish volume growth and higher than expected fiscal excise duty impact; strong price growth maintained even in the challenging current operating environment...
More from GlaxoSmithKline Consumer Healthcare Ltd.
Recommended